Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histidine triad nucleotide binding protein 2 pseudogene 1 (HINT2P1) is a **pseudogene**, meaning it is a DNA sequence homologous to a functional gene (in this case, HINT2), but is generally considered nonfunctional as it does not encode a protein product[1][3][4]. Pseudogenes can arise by duplication, retrotransposition, or mutation of coding genes and are typically transcriptionally inactive, although some are transcribed into noncoding RNAs[2][4]. Pseudogenes, including HINT2P1, are not classified as valid therapeutic targets because they do not produce proteins and have no documented drug interactions or direct disease relevance[1][2][3][4]. In rare cases, pseudogenes can regulate their parent or related genes via RNA interference mechanisms or as competing endogenous RNAs, but no specific such regulatory function is documented for HINT2P1.
None (not a protein-coding gene, not a druggable target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histidine triad nucleotide binding protein 2 pseudogene 1 (HINT2P1).